A Randomized, Double-blind, Placebo-controlled Phase Ⅱ Clinical Study to Evaluate the Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccine (Vero Cells) in Healthy Population Aged 3 to 17 Years
Latest Information Update: 04 Aug 2023
At a glance
- Drugs COVID-2019 vaccine-Shenzhen Kangtai Biological Products (Primary)
- Indications COVID 2019 infections
- Focus Pharmacodynamics
- Sponsors Shenzhen Kangtai Biological Products
- 20 Aug 2021 New trial record